Epizyme, Inc. (EPZM) Given Consensus Rating of “Buy” by Brokerages
Epizyme, Inc. (NASDAQ:EPZM) has received an average recommendation of “Buy” from the fourteen research firms that are covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $23.13.
A number of brokerages have recently weighed in on EPZM. BidaskClub downgraded Epizyme from a “sell” rating to a “strong sell” rating in a report on Friday, July 28th. Jefferies Group LLC began coverage on Epizyme in a report on Wednesday, September 20th. They issued a “buy” rating and a $23.00 price target for the company. Citigroup Inc. boosted their price target on Epizyme from $20.00 to $22.00 and gave the company a “buy” rating in a report on Friday, June 16th. Royal Bank Of Canada set a $20.00 price target on Epizyme and gave the company a “buy” rating in a report on Saturday, August 5th. Finally, Zacks Investment Research upgraded Epizyme from a “hold” rating to a “buy” rating and set a $16.00 price target for the company in a report on Tuesday, July 18th.
WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/12/epizyme-inc-epzm-given-consensus-rating-of-buy-by-brokerages.html.
In related news, insider Peter Tai-Ching Ho sold 15,000 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $16.81, for a total transaction of $252,150.00. Following the completion of the transaction, the insider now directly owns 23,123 shares in the company, valued at approximately $388,697.63. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, Director David M. Mott acquired 200,000 shares of the stock in a transaction that occurred on Monday, September 18th. The shares were bought at an average price of $15.25 per share, with a total value of $3,050,000.00. Following the completion of the purchase, the director now owns 6,000 shares in the company, valued at $91,500. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 45,000 shares of company stock valued at $688,950. 25.20% of the stock is owned by company insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Legal & General Group Plc grew its stake in Epizyme by 8.9% during the 1st quarter. Legal & General Group Plc now owns 9,684 shares of the biopharmaceutical company’s stock worth $165,000 after buying an additional 795 shares during the last quarter. UBS Asset Management Americas Inc. bought a new position in Epizyme during the 1st quarter worth $175,000. BB&T Securities LLC bought a new position in Epizyme during the 2nd quarter worth $181,000. Trexquant Investment LP bought a new position in Epizyme during the 2nd quarter worth $184,000. Finally, SG Americas Securities LLC grew its stake in Epizyme by 83.3% during the 2nd quarter. SG Americas Securities LLC now owns 13,364 shares of the biopharmaceutical company’s stock worth $202,000 after buying an additional 6,072 shares during the last quarter. Hedge funds and other institutional investors own 72.23% of the company’s stock.
Epizyme (NASDAQ:EPZM) opened at 17.95 on Thursday. The firm has a 50-day moving average of $17.68 and a 200 day moving average of $15.46. The stock’s market capitalization is $1.05 billion. Epizyme has a 52 week low of $8.38 and a 52 week high of $20.45.
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Friday, August 4th. The biopharmaceutical company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.08. The business had revenue of $10.00 million for the quarter, compared to analysts’ expectations of $3.95 million. During the same quarter in the prior year, the firm earned ($0.49) earnings per share. Epizyme’s revenue for the quarter was up 2027.7% compared to the same quarter last year. On average, analysts anticipate that Epizyme will post ($2.36) EPS for the current year.
Epizyme Company Profile
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company is engaged in the discovery and development of novel epigenetic therapies for cancer patients. The Company develops small molecule inhibitors of a class of enzymes known as histone methyltransferases (HMTs).
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.